Comparison of primary tumor maximal standardized uptake value (SUVmax) on preoperative [18F]fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT) and histological subtype in patients with non-small cell lung cancer (NSCLC)

7571 Background: The routine preoperative use of PET/CT in patients with potentially resectable NSCLC is rapidly expanding. The SUVmax is a semiquantitative measure of metabolic activity that can distinguish benign from malignant tissue but published data are conflicting regarding its ability to discriminate between major histological subtypes. Methods: Pathology and PET/CT reports of 39 NSCLC patients who underwent a preoperative scan and curative resection at the McGill University Health Centre were reviewed. Only patients with Adenocarcinoma (AC), Squamous Cell carcinoma (SC), or Large Cell carcinoma (LC), and definitive pathological staging, were included. The SUVmax values for each histological subtype, along with primary tumor sizes, were compared using F test and t-test analyses. Results: The 15 patients with SC and 5 with LC histology were found to have significantly greater preoperative SUVmax values than the 19 patients with AC (mean 12.7 and 17.2 vs. 9.4, respectively, P < 0.05), despite the fact that no significant differences in tumor size were observed between histological subtypes. Patients with LC histology displayed higher SUVmax values than patients with SC histology, but this was not found to be significant (P = 0.057).Conclusions: These data suggest that SC pulmonary tumors have significantly greater uptake on PET/CT than AC tumors. This finding may be helpful in the future when sufficient tissue cannot be obtained for pathological diagnosis or to identify the predominant pathology of mixed tumors. Larger studies are required to confirm our results. [Table: see text] No significant financial relationships to disclose.

Download Full-text

Sarcoid Reaction in Primary Tumor of Bronchogenic Large Cell Carcinoma Accompanied with Massive Necrosis.

Internal Medicine ◽

10.2169/internalmedicine.40.127 ◽

2001 ◽

Vol 40 (2) ◽

pp. 127-130 ◽

Cited By ~ 3

Author(s):

Kosuke KASHIWABARA ◽

Masakazu TOYONAGA ◽

Yuji YAMAGUCHI ◽

Hiroyuki NAKAMURA ◽

Seigo HIRAYAMA ◽

...

Keyword(s):

Cell Carcinoma ◽

Primary Tumor ◽

Large Cell Carcinoma ◽

Large Cell ◽

Sarcoid Reaction ◽

Massive Necrosis

Download Full-text

The role of surgery in the management of selected patients with small-cell carcinoma of the lung.

Journal of Clinical Oncology ◽

10.1200/jco.1987.5.5.697 ◽

1987 ◽

Vol 5 (5) ◽

pp. 697-702 ◽

Cited By ~ 48

Author(s):

R R Baker ◽

D S Ettinger ◽

J D Ruckdeschel ◽

J C Eggleston ◽

M F McKneally ◽

...

Keyword(s):

Lymph Nodes ◽

Cell Carcinoma ◽

Small Cell Carcinoma ◽

Primary Tumor ◽

Residual Disease ◽

Large Cell Carcinoma ◽

Large Cell ◽

Small Cell ◽

Operative Specimen

This study was designed to evaluate the efficacy of surgical resection of the primary tumor and lymph nodes in patients with localized small-cell carcinoma who had responded to induction chemotherapy. The study was performed in 37 patients who received two cycles of chemotherapy consisting of cyclophosphamide, doxorubicin, and etoposide. Those patients who achieved a complete or partial (greater than 50%) response were evaluated for thoracotomy and the primary tumor and regional lymph nodes excised when feasible. Postoperatively, the patients received prophylactic cranial irradiation and were maintained on the same chemotherapy for an average of 11 months. Twelve patients were resected and found to have residual small-cell carcinoma in the operative specimen (ten) or no residual disease (two). Seven of these patients (58%) are alive without evidence of disease (median follow-up, 24 months). Seven other patients who were resected proved to have either residual foci or small-cell carcinoma mixed with adenocarcinoma or large-cell carcinoma (four) or only focal areas of adenocarcinoma, large-cell carcinoma, or squamous-cell carcinoma with no evidence of residual small-cell carcinoma. Five of these patients (71%) are alive without evidence of disease (median follow-up, 36 months). Two of the 16 patients who were not resected but treated with chemotherapy and radiation are alive at 15 and 31 months without evidence of disease, the other 14 are dead of disease.

Download Full-text

Interim 4′-[methyl-11C]-thiothymidine PET for predicting the chemoradiotherapeutic response in head and neck squamous cell carcinoma: comparison with [18F]FDG PET

EJNMMI Research ◽

10.1186/s13550-021-00749-y ◽

2021 ◽

Vol 11 (1) ◽

Author(s):

Katsuya Mitamura ◽

Takashi Norikane ◽

Yuka Yamamoto ◽

Kengo Fujimoto ◽

Yasukage Takami ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Head And Neck ◽

Squamous Cell ◽

Fdg Pet ◽

Tumor Volume ◽

Standardized Uptake Value ◽

Complete Response ◽

Neck Squamous Cell Carcinoma ◽

Pet Ct

Abstract Purpose We investigated the potential of interim 4′-[methyl-11C]thiothymidine ([11C]4DST) PET for predicting the chemoradiotherapeutic response for head and neck squamous cell carcinoma (HNSCC), in comparison with 2-deoxy-2-[18F]fluoro-D-glucose ([18F]FDG) PET. Methods A total of 32 patients with HNSCC who underwent both [11C]4DST and [18F]FDG PET/CT before therapy (baseline) and at approximately 40 Gy point during chemoradiotherapy (interim) were available for a retrospective analysis of prospectively collected data. The baseline was treatment-naïve PET/CT scan as part of staging. The maximum standardized uptake value (SUVmax), metabolic tumor volume (MTV) from [18F]FDG PET or proliferative tumor volume (PTV) from [11C]4DST PET, and total lesion glycolysis (TLG) from [18F]FDG PET or total lesion proliferation (TLP) from [11C]4DST PET were measured. MTV or PTV was defined as the volume with an SUVmax greater than 2.5. The differences in SUVmax (ΔSUVmax), MTV (ΔMTV) or PTV (ΔPTV) and TLG (ΔTLG) or TLP (ΔTLP) from baseline to interim PET scans were calculated. Patients without or with evidence of residual or recurrent disease at 3 months after completion of chemoradiotherapy were classified as showing a complete response (CR) and non-CR, respectively. Results All patients showed increased uptake in primary tumor on baseline [11C]4DST and [18F]FDG PET studies. All patients showed increased uptake on interim [18F]FDG PET, whereas 18 patients showed no increased uptake on interim [11C]4DST PET. After chemoradiotherapy, 25 patients were found to be in CR group and 7 to be in non-CR group. [11C]4DST ΔSUVmax, ΔPTV, and ΔTLP for CR group showed significantly greater reductions than the corresponding values for non-CR group (P = 0.044, < 0.001, < 0.001, respectively). However, there were no significant differences in [18F]FDG ΔSUVmax, ΔMTV, or ΔTLG between CR group and non-CR group. [11C]4DST ΔMTV of -90 was the best cutoff value for the early identification of patients with non-CR. Conclusion These preliminary results suggest that interim [11C]4DST PET might be useful for predicting the chemoradiotherapeutic response in patients with HNSCC, in comparison with [18F]FDG PET.

Download Full-text